Neuroprotective influence of sitagliptin against cisplatin-induced neurotoxicity, biochemical and behavioral alterations in Wistar rats

  • Yuxin Li
  • Maoyong ZhengEmail author
  • Sushil Kumar Sah
  • Anurag Mishra
  • Yogendra Singh


Cisplatin has been extensively used as a chemotherapeutic agent since around 40 years, though its usage is limited due to severe adverse effects like neurotoxicity that might be because of oxidative stress. Hence, the present study was planned to investigate the possible protective role of sitagliptin against cisplatin-associated neurotoxic, biochemical, and behavioral alterations in male Wistar rats. Sitagliptin is a dipeptidyl peptidase-4 inhibitor that shows dual effects by improving the control on metabolism as well as decreasing the debility in cognitive function that is associated with increased insulin sensitivity and antioxidant property. For the in vitro assay, cultured rat pheochromocytoma (PC12) cells were exposed to different concentrations (10, 20, and 50 mM) of sitagliptin for 24 h. Cisplatin at 5 mM concentrations was added and cell viability was assessed using MTT assay. For in vivo study, animals were divided into four groups. Group I (Vehicle control): animals were administered 0.9% (w/v) of normal saline (1 mL/100 g; p.o.). Group II (Cisplatin): animals were treated with cisplatin (2 mg/kg; i.p.). Group III (Cisplatin + sitagliptin): animals were administered cisplatin along with sitagliptin. Group IV (Sitagliptin): animals were given sitagliptin (10 mg/kg; p.o.). All the treatments were administered for 8 weeks. On last day of treatment, behavioral evaluations including locomotor and rotarod studies were performed. In addition, several antioxidant enzymes were also estimated from cerebellum tissues; such as levels of thiobarbituric acid reactive substance (TBARS) were determined as a marker of lipid peroxidation, reduced glutathione (GSH) and catalase (CAT) were also estimated. Histological study of cerebellum tissue was also performed after performing the behavioral study. Exposure to cisplatin decreased cell viability in PC12 cells which were significantly increased by co-treatment with sitagliptin. In in vivo study, cisplatin significantly elevated the level of TBARS and reduced the level of antioxidant enzymes such as GSH and CAT which were significantly restored in sitagliptin + cisplatin group of rats. In addition, cisplatin impaired performance on the locomotor and rotarod activities, whereas sitagliptin significantly improved the performance of both activities. These results suggested the neuroprotective influence of sitagliptin by protecting cerebellum part of brain against cisplatin-induced toxicity.


Cisplatin Locomotor PC12 cells Rotarod Sitagliptin TBARS 


Compliance with ethical standards

Conflict of interest

All the authors declare that they have no conflict of interest.


  1. 1.
    Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 0:364–378. CrossRefGoogle Scholar
  2. 2.
    Florea A-M, Büsselberg D (2011) Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3:1351–1371. CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Cavaletti G, Bogliun G, Crespi V, Marzorati L, Zincone A, Marzola M, Rota S, Galli A, Tredici P, Tredici G (1997) Neurotoxicity and ototoxicity of cisplatin plus paclitaxel in comparison to cisplatin plus cyclophosphamide in patients with epithelial ovarian cancer. J Clin Oncol 15:199–206. CrossRefPubMedGoogle Scholar
  4. 4.
    Canta A, Pozzi E, Carozzi VA (2015) Mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy (CIPN). Toxics 3:198–223. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Zhou W, Kavelaars A, Heijnen CJ (2016) Metformin prevents cisplatin-induced cognitive impairment and brain damage in mice. PLoS ONE 11:e0151890. CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Schwartz SA, Weil RJ, Thompson RC, Shyr Y, Moore JH, Toms SA, Johnson MD, Caprioli RM (2005) Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res 65:7674–7681. CrossRefPubMedGoogle Scholar
  7. 7.
    Gallwitz B (2007) Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc) 43:13–25. CrossRefGoogle Scholar
  8. 8.
    Pais R, Gribble FM, Reimann F (2016) Stimulation of incretin secreting cells. Ther Adv Endocrinol Metab 7:24–42. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Christensen MB (2016) Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans. Dan Med J 63Google Scholar
  10. 10.
    Campbell Jonathan E, Drucker Daniel J (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17:819–837. CrossRefPubMedGoogle Scholar
  11. 11.
    Chang MW, Chen CH, Chen YC, Wu YC, Zhen YY, Leu S, Tsai TH, Ko SF, Sung PH, Yang CC, Chiang HJ, Chang HW, Chen YT, Yip HK (2015) Sitagliptin protects rat kidneys from acute ischemia-reperfusion injury via upregulation of GLP-1 and GLP-1 receptors. Acta Pharmacol Sinica 36:119–130. CrossRefGoogle Scholar
  12. 12.
    Sahebgharani M, Nejati M, Sepehrizadeh Z, Khorramizadeh MR, Bahrololoumi-Shapourabadi M, Hashemi-Bozchlou S, Esmaeili J, Ghazi-Khansari M (2008) Lithium chloride protects PC12 pheochromocytoma cell line from morphine-induced apoptosis. Arch Iran Med 11:639–648PubMedGoogle Scholar
  13. 13.
    Gupta G, Jia Jia T, Yee Woon L, Kumar Chellappan D, Candasamy M, Dua K (2015) Pharmacological evaluation of antidepressant-like effect of genistein and its combination with amitriptyline: an acute and chronic study. Adv Pharmacol Sci 2015:164943. CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Deacon RMJ (2013) Measuring Motor Coordination in Mice. J Vis Exp. CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bradley-Whitman MA, Lovell MA (2015) Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update. Arch Toxicol 89:1035–1044. CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Saing T, Lagman M, Castrillon J, Gutierrez E, Guilford FT, Venketaraman V (2016) Analysis of glutathione levels in the brain tissue samples from HIV-1-positive individuals and subject with Alzheimer’s disease and its implication in the pathophysiology of the disease process. BBA Clin 6:38–44. CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Sani M, Sebai H, Gadacha W, Boughattas NA, Reinberg A, Mossadok BA (2006) Catalase activity and rhythmic patterns in mouse brain, kidney and liver. Comp Biochem Physiol B Biochem Mol Biol 145:331–337. CrossRefPubMedGoogle Scholar
  18. 18.
    Astolfi L, Ghiselli S, Guaran V, Chicca M, Simoni EDI, Olivetto E, Lelli G, Martini A (2013) Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation. Oncol Rep 29:1285–1292. CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Barrera G (2012) Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol 2012:137289. CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Almutairi MM, Alanazi WA, Alshammari MA, Alotaibi MR, Alhoshani AR, Al-Rejaie SS, Hafez MM, Al-Shabanah OA (2017) Neuro-protective effect of rutin against Cisplatin-induced neurotoxic rat model. BMC Complement Altern Med 17:472. CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O (2012) Oxidative stress and antioxidant defense. World Allergy Org J 5:9–19. CrossRefGoogle Scholar
  22. 22.
    Nita M, Grzybowski A (2016) The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. Oxid Med Cell Longev 2016:3164734. CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Nader MA, Ateyya H, El-Shafey M, El-Sherbeeny NA (2018) Sitagliptin enhances the neuroprotective effect of pregabalin against pentylenetetrazole-induced acute epileptogenesis in mice: implication of oxidative, inflammatory, apoptotic and autophagy pathways. Neurochem Int 115:11–23. CrossRefPubMedGoogle Scholar
  24. 24.
    Ding M, Weng C, Fan S, Cao Q, Lu Z (2017) Purkinje cell degeneration and motor coordination deficits in a new mouse model of autosomal recessive spastic ataxia of charlevoix-saguenay. Front Mol Neurosci 10:121. CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Mahesh R, Kumar B, Jindal A, Bhatt S, Devadoss T, Pandey DK (2012) Antidepressant-like activity of (4-phenylpiperazin-1-yl) (quinoxalin-2-yl) methanone (4a), a novel 5-HT(3) receptor antagonist: an investigation in behaviour-based rodent models of depression. Indian J Pharmacol 44:560–565. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Almaghrabi OA (2015) Molecular and biochemical investigations on the effect of quercetin on oxidative stress induced by cisplatin in rat kidney. Saudi J Biol Sci 22:227–231. CrossRefPubMedGoogle Scholar
  27. 27.
    Phaniendra A, Jestadi DB, Periyasamy L (2015) Free radicals: properties, sources, targets, and their implication in various diseases. Indian J Clin Biochem 30:11–26. CrossRefPubMedGoogle Scholar
  28. 28.
    Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC (2009) Mitochondrial glutathione, a key survival antioxidant. Antioxid Redox Signal 11:2685–2700. CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Schmitt B, Vicenzi M, Garrel C, Denis FM (2015) Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: a comparative crossover study. Redox Biol 6:198–205. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Akman T, Akman L, Erbas O, Terek MC, Taskiran D, Ozsaran A (2015) The preventive effect of oxytocin to cisplatin-induced neurotoxicity: an experimental rat model. Biomed Res Int 2015:167235. CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Abo-Haded HM, Elkablawy MA, Al-Johani Z, Al-Ahmadi O, El-Agamy DS (2017) Hepatoprotective effect of sitagliptin against methotrexate induced liver toxicity. PLoS ONE 12:e0174295. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Yuxin Li
    • 1
  • Maoyong Zheng
    • 2
    Email author
  • Sushil Kumar Sah
    • 3
  • Anurag Mishra
    • 4
  • Yogendra Singh
    • 5
  1. 1.Department of NeurologyThe Second Affiliated Hospital of Xi’an Medical UniversityXi’anChina
  2. 2.Department of NeurologyShandong Provincial Western HospitalJinanChina
  3. 3.Department of PharmacologyBirat Medical CollegeBiratnagarNepal
  4. 4.School of PharmacySuresh Gyan Vihar UniversityJaipurIndia
  5. 5.Department of PharmacologyMahatma Gandhi University of Medical Sciences & TechnologyJaipurIndia

Personalised recommendations